Characterization of the self-association of human interferon-α2b, albinterferon-α2b, and pegasys

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 68-80

  Li, Yiming ^a,c   Stafford, Walter F ^b   Hesselberg, Mark ^a   Hayes, David ^b,c   Wu, Zhuchun ^a   Byrne, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Analytical ultracentrifugation; Biopharmaceuticals characterization; Macromolecular prodrugs; Physical characterization; Physicochemical properties; Proteins

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; POLYPEPTIDE;

ARTICLE; PH; SEDIMENTATION RATE; STATIC ELECTRICITY; STOICHIOMETRY; ULTRACENTRIFUGATION;

EID: 82255166925     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22751     Document Type: Article

References (31)

1. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. 2007. Interferon: Cellular executioner or white knight? Curr Med Chem 14(12):1279-1289.
2. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. 2004. Human interferons alpha, beta and omega. Growth Factors 22(4):243-251.
3. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303(2):540-548.
4. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. 2001. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12(2):195-202.
5. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, Senn H. 2005. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem 16(3):504-517.
6. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T. 2003. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 30(1):78-87.
7. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54(4):547-570.
8. Karnam US, Reddy KR. 2003. Pegylated interferons. Clin Liver Dis 7(1):139-148.
9. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. 2006. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44(4):671-678.
10. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM. 2006. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 11(1):35-45.
11. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. 2007. Albinterferon alpha-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25(12):1411-1419.
12. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12(5):903-913.
13. Clodfelter DK, Pekar AH, Rebhun DM, Destrampe KA, Havel HA, Myers SR, Brader ML. 1998. Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm Res 15(2):254-262.
14. DeFelippis MR, Chance RE, Frank BH. 2001. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst 18(2):201-264.
15. Marianayagam NJ, Sunde M, Matthews JM. 2004. The power of two: Protein dimerization in biology. Trends Biochem Sci 29(11):618-625.
16. Wiseman RL, Green NS, Kelly JW. 2005. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: Implications for transthyretin amyloidosis. Biochemistry 44(25):9265-9274.
17. Cromwell MEM, Felten C, Flores H, Liu J, Shire SJ. 2006. Self-association of therapeutic proteins: Implications for product development. In Misbehaving proteins: Protein (Mis)folding, aggregation, and stability; Murphy RM, Tsai AM, Eds. New York: Springer.
18. Edelhoch H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6(7):1948-1954.
19. Laue TM, Shah BD, Ridgeway TM, Pelletier SL. 1992. Computer-aided interpretation of analytical sedimentation data for proteins. In Analytical ultracentrifugation in biochemistry and polymer science; Harding SE, Rowe AJ, Horton JC, Eds. Cambridge, UK: Royal Society of Chemistry.
20. Schuck P. 2003. On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. Anal Biochem 320(1):104-124.
21. Schuck P, Rossmanith P. 2000. Determination of the sedimentation coefficient distribution by least-squares boundary modeling. Biopolymers 54(5):328-341.
22. Stafford WF, Sherwood PJ. 2004. Analysis of heterologous interacting systems by sedimentation velocity: Curve fitting algorithms for estimation of sedimentation coefficients, equilibrium and kinetic constants. Biophys Chem 108(1-3):231-243.
23. Gokarn YR. 2003. Hydrodynamic behavior and thermal stability of a pegylated protein: Studies with hen egg lysozyme. Ph.D. Thesis. Durham: University of New Hampshire.
24. Barth HG, Garlin FJ. 1984. A review of polymer shear degradation in size-exclusion chromatography. Journal Liq Chromatogr 7:1717-1738.
25. Harpur AG, Layton MJ, Das P, Bottomley MJ, Panayotou G, Driscoll PC, Waterfield MD. 1999. Intermolecular interactions of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem 274(18):12323-12332.
26. Kuhlman B, Yang HY, Boice JA, Fairman R, Raleigh DP. 1997. An exceptionally stable helix from the ribosomal protein L9: Implications for protein folding and stability. J Mol Biol 270(5):640-647.
27. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96:268-279.
28. Philo J. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564-E571.
29. Schachman HK. 1959. Ultracentrifugation in biochemistry. New York: Academic Press.
30. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
31. De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490.